6-乙氧基-3-硝基吡啶-2-胺 | 40851-82-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 6-乙氧基-3-硝基吡啶-2-胺
• 英文名称: 6-ethoxy-3-nitropyridin-2-amine
• 英文别名: 6-ethoxy-3-nitro-[2]pyridylamine；6-Aethoxy-3-nitro-[2]pyridylamin；2-amino-6-ethoxy-3-nitropyridine
• CAS: 40851-82-9
• 化学式: C₇H₉N₃O₃
• 分子量: 183.167
• InChiKey: FOGGQBVTIHSOGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  129.5-130 °C(Solv: ethanol (64-17-5))
• 沸点：
  345.6±37.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  94
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-乙氧基-3-硝基吡啶-2-胺 在 N-溴代丁二酰亚胺(NBS) 、 亚硝酸特丁酯 、 copper(l) chloride 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.5h， 生成 3-溴-6-氯-2-乙氧基-5-硝基吡啶
  参考文献：
  名称：

  [EN] PYRIDO[2,3-B] [1,4] OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4] OXAZEPINES AS IAP ANTAGONISTS
  [FR] PYRIDO[2, 3-B] [1, 4] OXAZINES OU TÉTRAHYDROPYRIDO [2, 3-B] [1, 4] OXAZÉPINES UTILISÉES EN TANT QU'ANTAGONISTES D'IAP

  摘要：

  本文揭示了作为IAPs（抑制凋亡蛋白）拮抗剂使用的新型2,3-二氢-1H-吡啶[2,3-b][1,4]噁嗪或1,2,3,4-四氢吡啶[2,3-b][1,4]噁烯衍生物。本文还揭示了这些拮抗剂用于诱导或增加细胞对凋亡细胞死亡的敏感性，以及利用这些化合物治疗增殖性疾病如癌症的用途。

  公开号：

  WO2021244608A1
• 作为产物：
  描述：

  2-溴-6-乙氧基吡啶 在 乙醇 、 硫酸 、 氨 、 硝酸 作用下， 生成 6-乙氧基-3-硝基吡啶-2-胺
  参考文献：
  名称：

  den Hertog; Jouwersma, Recueil des Travaux Chimiques des Pays-Bas, 1953, vol. 72, p. 125,131

  摘要：

  DOI：

文献信息

• Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3- b ]pyrazine-2,3-dione as a novel potent d -amino acid oxidase inhibitor
  作者：Dongsheng Xie、Jun Lu、Jin Xie、Junjun Cui、Teng-Fei Li、Yan-Chao Wang、Yuan Chen、Nian Gong、Xin-Yan Li、Lei Fu、Yong-Xiang Wang

  DOI：10.1016/j.ejmech.2016.04.017

  日期：2016.7

  A series of 5-azaquinoxaline-2,3-dione derivatives were synthesized and evaluated on d-amino acid oxidase (DAAO) inhibition as potential α-hydroxylactam-based inhibitors. The potent inhibitory activities in vitro suggested that 5-nitrogen could significantly enhance the binding affinity by strengthening relevant hydrogen bond interactions. The analgesic effects of intrathecal and systemic injection

  合成了一系列5-氮杂喹喔啉-2,3-二酮衍生物，并评估了其作为潜在的基于α-羟基内酰胺的抑制剂对d-氨基酸氧化酶（DAAO）的抑制作用。体外的强抑制活性表明5-氮可以通过增强相关的氢键相互作用来显着增强结合亲和力。研究了鞘内和全身注射8-氯-1,4-二氢吡啶并[2,3- b ]吡嗪-2,3-二酮（5-氮杂喹喔啉-2,3-二酮的代表分子）的镇痛作用。啮齿动物。这项研究不仅证实了DAAO抑制剂的镇痛作用，而且还提供了一类具有口服应用潜力的新型化学实体，可用于治疗慢性疼痛和吗啡镇痛耐受性。
• Heterocyclic-ring condensed benzothiazine compound
  申请人：Eisai Co., Ltd.

  公开号：US06583138B1

  公开（公告）日：2003-06-24

  The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like. Further, the heterocyclic ring condensed benzothiazine compound of the present invention, its pharmacologically acceptable salt or hydrates thereof is represented by the following formula: In the formula, the ring Het represents an unsaturated heterocyclic ring; R1 and R2 are the same as or different from each other, and each represents halogen atom, a lower alkyl group that may be substituted with a halogen atom, a lower alkoxy group that may be substituted with a halogen atom, a lower alkyl lower alkoxy group, cyano group; D represents a lower alkylene group and the like that may have a substituent; Q represents, for example, the formula —NR20R2 (in the formula, R20 and R21 are the same as or different from each other, and each represents hydrogen atom, a lower alkyl group that may be substituted with a halogen atom, an aryl group that may have a substituent, an arylalkyl group that may have a substituent, a heteroaryl group that may have a substituent or a heteroarylalkyl group that may have a substituent, or R20 and R21 may form a 3- to 8-membered ring along with the nitrogen atom to which they are bound); and x represents an integer of from 1 to 2.

  该发明提供了一种新型的杂环环扎缩苯并噻嗪化合物，对于预防或治疗组织胺、白三烯等参与的疾病有效。本发明的杂环环扎缩苯并噻嗪化合物或其药理学上可接受的盐对于预防或治疗组织胺、白三烯等化学介质参与的疾病（例如哮喘、过敏性鼻炎、特应性皮炎、荨麻疹、花粉热、胃肠道过敏、食物过敏等）有效。此外，本发明的杂环环扎缩苯并噻嗪化合物、其药理学上可接受的盐或其水合物由以下公式表示：在该公式中，环Het代表不饱和杂环环；R1和R2相同或不同，每个代表卤素原子、可能被卤素原子取代的较低烷基基团、可能被卤素原子取代的较低烷氧基团、较低烷基较低烷氧基团、氰基；D代表可能有取代基的较低烷基基团等；Q代表，例如，式—NR20R2（在该式中，R20和R21相同或不同，每个代表氢原子、可能被卤素原子取代的较低烷基基团、可能有取代基的芳基团、可能有取代基的芳基烷基团、可能有取代基的杂芳基团或可能有取代基的杂芳基烷基团，或者R20和R21可以与它们结合的氮原子一起形成3-至8-成员环）；x代表1到2的整数。
• 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20120115902A1

  公开（公告）日：2012-05-10

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供了公式（I）的化合物，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义在说明中给出，并且其药学上可接受的盐，在希望和/或需要抑制MAPEG家族成员活性的疾病治疗中非常有用，特别是在炎症和/或癌症治疗中。
• HETEROCYCLE-FUSED BENZOTHIAZINE DERIVATIVES
  申请人：Eisai Co., Ltd.

  公开号：EP1057830A1

  公开（公告）日：2000-12-06

  The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like. Further, the heterocyclic ring condensed benzothiazine compound of the present invention, its pharmacologically acceptable salt or hydrates thereof is represented by the following formula: In the formula, the ring Het represents an unsaturated heterocyclic ring; R1 and R2 are the same as or different from each other, and each represents halogen atom, a lower alkyl group that may be substituted with a halogen atom, a lower alkoxy group that may be substituted with a halogen atom, a lower alkyl lower alkoxy group, cyano group; D represents a lower alkylene group and the like that may have a substituent; Q represents, for example, the formula -NR20R21 (in the formula, R20 and R21 are the same as or different from each other, and each represents hydrogen atom, a lower alkyl group that may be substituted with a halogen atom, an aryl group that may have a substituent, an arylalkyl group that may have a substituent, a heteroaryl group that may have a substituent or a heteroarylalkyl group that may have a substituent, or R20 and R21 may form a 3- to 8-membered ring along with the nitrogen atom to which they are bound); and x represents an integer of from 1 to 2.

  本发明提供了一种新型杂环缩合苯并噻嗪化合物，可有效预防或治疗组胺、白三烯等参与的疾病。本发明的杂环缩合苯并噻嗪化合物或其药理学上可接受的盐可有效预防或治疗化学介质（如组胺、白三烯等）参与的疾病，如哮喘、过敏性苍白喉、特应性皮炎、荨麻疹、花粉症、胃肠道过敏、食物过敏等。此外，本发明的杂环缩合苯并噻嗪化合物、其药理学上可接受的盐或其水合物由下式表示： 式中，环 Het 代表不饱和杂环；R1 和 R2 彼此相同或不同，各自代表卤原子、可被卤原子取代的低级烷基、可被卤原子取代的低级烷氧基、低级烷基低级烷氧基、氰基；D 代表可具有取代基的低级亚烷基等；Q 代表例如式-NR20R21（式中，R20 和 R21 彼此相同或不同，且各自代表氢原子、可被卤素原子取代的低级烷基、可具有取代基的芳基、可具有取代基的芳烷基、可具有取代基的杂芳基或可具有取代基的杂芳基烷基，或 R20 和 R21 可与它们结合的氮原子一起形成 3 至 8 元环）；x 代表 1 至 2 的整数。
• TAKEHDA, XARUKI;IIDZUMI, KEHNITI
  作者：TAKEHDA, XARUKI、IIDZUMI, KEHNITI

  DOI：——

  日期：——